Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04907539Phase 2Completed

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Role: lead

NCT04907851Phase 2Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Role: lead

NCT03447470Phase 1Completed

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Role: lead

NCT05570058Phase 2Active Not Recruiting

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Role: lead

NCT04931147Phase 1Completed

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Role: lead

All 5 trials loaded